PMID- 35658248
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220608
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 150
DP  - 2022 Jun
TI  - Propofol pretreatment alleviates mast cell degranulation by inhibiting SOC to 
      protect the myocardium from ischemia-reperfusion injury.
PG  - 113014
LID - S0753-3322(22)00403-6 [pii]
LID - 10.1016/j.biopha.2022.113014 [doi]
AB  - Propofol (PPF) has a protective effect on myocardial ischemia-reperfusion (I/R) 
      injury (MIRI). The purpose of this study was to investigate whether the 
      myocardial protective effect of propofol is related to the inhibition of mast 
      cell degranulation and explore the possible mechanisms involved. Our in vivo 
      results showed that compared with the sham group, cardiac function, infarct size, 
      histopathological damage, apoptosis, and markers of myocardial necrosis were 
      significantly increased in the ischemia-reperfusion group, and propofol 
      pretreatment alleviated these effects. In the coculture system, propofol-treated 
      mast cells reduced their tryptase activity, resulting in cardiomyocyte protective 
      effects, such as decreased apoptosis of cardiomyocytes and decreased expression 
      of myocardial necrosis markers. Finally, experimental results in vitro revealed 
      that thapsigargin (TG) can increase mast cell degranulation, tryptase release, 
      calcium ion concentration, and the expression of STIM1 and Orai1 induced by H/R, 
      but propofol pretreatment can partially reverse the above effects. These results 
      suggested that the cardioprotective effect of propofol is achieved in part by 
      inhibiting calcium influx through store-operated Ca(2+) channels (SOCs) and thus 
      alleviating mast cell degranulation.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Li, Yaozu
AU  - Li Y
AD  - School of Anesthesiology, Shandong Provincial Medicine and Health Key Laboratory 
      of Clinical Anesthesia, Weifang Medical University, Weifang 261053, China.
FAU - Sun, Xiaotong
AU  - Sun X
AD  - School of Anesthesiology, Shandong Provincial Medicine and Health Key Laboratory 
      of Clinical Anesthesia, Weifang Medical University, Weifang 261053, China.
FAU - Juan, Zhaodong
AU  - Juan Z
AD  - School of Anesthesiology, Shandong Provincial Medicine and Health Key Laboratory 
      of Clinical Anesthesia, Weifang Medical University, Weifang 261053, China. 
      Electronic address: juanzd@wfmc.edu.cn.
FAU - Guan, Xuehao
AU  - Guan X
AD  - School of Anesthesiology, Shandong Provincial Medicine and Health Key Laboratory 
      of Clinical Anesthesia, Weifang Medical University, Weifang 261053, China.
FAU - Wang, Mingling
AU  - Wang M
AD  - School of Anesthesiology, Shandong Provincial Medicine and Health Key Laboratory 
      of Clinical Anesthesia, Weifang Medical University, Weifang 261053, China.
FAU - Meng, Yanmei
AU  - Meng Y
AD  - School of Anesthesiology, Shandong Provincial Medicine and Health Key Laboratory 
      of Clinical Anesthesia, Weifang Medical University, Weifang 261053, China.
FAU - Ma, Ruijin
AU  - Ma R
AD  - School of Anesthesiology, Shandong Provincial Medicine and Health Key Laboratory 
      of Clinical Anesthesia, Weifang Medical University, Weifang 261053, China.
LA  - eng
PT  - Journal Article
DEP - 20220430
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - EC 3.4.21.59 (Tryptases)
RN  - SY7Q814VUP (Calcium)
RN  - YI7VU623SF (Propofol)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Calcium/metabolism
MH  - Cell Degranulation
MH  - Mast Cells
MH  - *Myocardial Infarction/metabolism
MH  - *Myocardial Reperfusion Injury/drug therapy/metabolism/prevention & control
MH  - Myocardium/pathology
MH  - *Propofol/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Tryptases/metabolism/pharmacology
OTO - NOTNLM
OT  - Mast cell
OT  - Myocardial ischemia/reperfusion injury
OT  - Propofol
OT  - Store operated Ca(2+) channels
EDAT- 2022/06/06 06:00
MHDA- 2022/06/09 06:00
CRDT- 2022/06/05 01:03
PHST- 2022/01/09 00:00 [received]
PHST- 2022/04/12 00:00 [revised]
PHST- 2022/04/19 00:00 [accepted]
PHST- 2022/06/05 01:03 [entrez]
PHST- 2022/06/06 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
AID - S0753-3322(22)00403-6 [pii]
AID - 10.1016/j.biopha.2022.113014 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2022 Jun;150:113014. doi: 10.1016/j.biopha.2022.113014. Epub 
      2022 Apr 30.